Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2016-03-21 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings
2016-03-21 Danish
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and details an agreement between Genmab, Janssen, and Roche regarding clinical studies for daratumumab in combination with atezolizumab. It announces future actions (initiation of Phase Ib studies) and provides background information on the drugs and the company. This type of announcement, which communicates specific, material, non-financial operational news to the market, fits best under the general category of regulatory announcements or press releases that are not specifically earnings, capital changes, or management changes. Since it is a formal announcement of a business/clinical development, and not a full financial report (10-K, IR) or a specific shareholder vote result (DVA), the most appropriate classification is Regulatory Filings (RNS), which serves as a broad category for material company news releases that don't fit elsewhere. It is not an Earnings Release (ER) as it contains no financial results, nor is it a Call Transcript (CT). It is too detailed to be a simple Report Publication Announcement (RPA).
2016-03-21 English
Genmab annoncerer studier med daratumumab i kombination med atezolizumab i en solid tumor indikation og i myelomatose
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding the initiation of new clinical studies for their drug Daratumumab. It provides details on the collaboration with Roche/Genentech and the nature of the clinical trials. It does not fit into financial reporting categories like 10-K or IR, nor is it a specific shareholder meeting document. As it is a general regulatory/corporate announcement regarding business operations and clinical development, it falls under the 'Regulatory Filings' (RNS) category.
2016-03-21 English
Genmab annoncerer studier med daratumumab i kombination med atezolizumab i en solid tumor indikation og i myelomatose
Regulatory Filings Classification · 71% confidence The document is a corporate press release (“Company Announcement”) describing the start of Phase Ib clinical studies and collaboration agreements. It contains no financial statements, management changes, dividend or voting results, nor does it present or announce the publication of a formal report. It is a general company regulatory announcement that does not fit any more specific filing category. Therefore, it defaults to the Regulatory Filings (RNS) category.
2016-03-21 English
AGM Information 2016
AGM Information Classification · 99% confidence The document explicitly states it is a 'Company Announcement' released immediately 'Following Genmab A/S' Annual General Meeting held on March 17, 2016'. The content details the subsequent constitution of the Board of Directors (appointment of Chairman/Deputy Chairman) and the decision to issue warrants to employees. This content relates directly to the governance and immediate post-meeting actions following the AGM. While it mentions the AGM, the primary focus is on the board constitution and warrant issuance, which are governance/capital structure related events occurring right after the meeting. However, since the context is explicitly tied to the AGM proceedings and subsequent board formation, and given the available codes, 'AGM-R' (AGM Information) is the most appropriate fit as it covers materials shared during or immediately following the AGM, especially concerning board composition changes. It is not a DEF 14A (Remuneration) or a general CAP (Financing Update) as the warrant issuance is a direct consequence of the meeting's mandate/structure.
2016-03-17 English
Share Issue/Capital Change 2016
Share Issue/Capital Change Classification · 99% confidence The document is titled 'Selskabsmeddelelse' (Company Announcement) and is dated March 17, 2016. The content details the constitution of the Board of Directors following the Annual General Meeting (AGM) and, crucially, the subsequent decision to grant warrants (stock options) to employees. This type of announcement, detailing board changes and specific capital/incentive structure decisions made immediately post-AGM, fits best under Capital/Financing Update (CAP) or potentially Board/Management Information (MANG). However, the primary focus shifts to the allocation of 24,350 warrants, which is a direct change to the capital structure/incentive plan. Since 'CAP' covers 'Updates on company fundraising, financing activities, or capital structure changes,' and warrant grants are a form of capital structure management/incentive, CAP is the most appropriate fit over MANG, which focuses only on personnel changes. It is not a full AGM presentation (AGM-R) or a voting result declaration (DVA), but a specific corporate action announcement following the meeting.
2016-03-17 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.